CC chemokine receptor 5 influences late-stage atherosclerosis.

Marlon P. Quinones,Hernan G. Martinez,Fabio Jimenez,C. Estrada,Molly Dudley,Opal Willmon,Hemant Kulkarni,R. Reddick,G. Fernandes,W. Kuziel,S. Ahuja,S. Ahuja

DOI: https://doi.org/10.1016/J.ATHEROSCLEROSIS.2007.03.026

IF: 5.3

2007-11-01

Atherosclerosis

Abstract:

What problem does this paper attempt to address?

Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis

Chen-Yi Yuan,Yuan-Cheng Gao,Yi Lin,Lin Liu,Xiao-Gang Shen,Wen-Li Zou,Min-Min Wang,Quan-Quan Shen,Li-Na Shao,Yue-Ming Liu,Jia-Wei Zhang,Zhi-Hui Pan,Yan Zhu,Jing-Ting Yu,Xu-Guang Yu,Bin Zhu

DOI: https://doi.org/10.1159/000534366

2023-01-01

American Journal of Nephrology

Abstract:Background: Mineralocorticoid receptor blockade could be a potential approach for the inhibition of chronic kidney disease (CKD) progression. The benefits and harms of different mineralocorticoid receptor antagonists (MRAs) in CKD are inconsistent. Objectives: The aim of the study was to summarize the benefits and harms of MRAs for CKD patients. Methods: We searched MEDLINE, EMBASE, and the Cochrane databases for trials assessing the effects of MRAs on non-dialysis-dependent CKD populations. Treatment and adverse effects were summarized using meta-analysis. Results: Fifty-three trials with 6 different MRAs involving 22,792 participants were included. Compared with the control group, MRAs reduced urinary albumin-to-creatinine ratio (weighted mean difference [WMD], −90.90 mg/g, 95% CI, −140.17 to −41.64 mg/g), 24-h urinary protein excretion (WMD, −0.20 g, 95% CI, −0.28 to −0.12 g), estimated glomerular filtration rate (eGFR) (WMD, −1.99 mL/min/1.73 m2, 95% CI, −3.28 to −0.70 mL/min/1.73 m2), chronic renal failure events (RR, 0.86, 95% CI, 0.79–0.93), and cardiovascular events (RR, 0.84, 95% CI, 0.77–0.92). MRAs increased the incidence of hyperkalemia (RR, 2.04, 95% CI, 1.73–2.40) and hypotension (RR, 1.80, 95% CI, 1.41–2.31). MRAs reduced the incidence of peripheral edema (RR, 0.65, 95% CI, 0.56–0.75) but not the risk of acute kidney injury (RR, 0.94, 95% CI, 0.79–1.13). Nonsteroidal MRAs (RR, 0.66, 95% CI, 0.57–0.75) but not steroidal MRAs (RR, 0.20, 95% CI, 0.02–1.68) significantly reduced the risk of peripheral edema. Steroidal MRAs (RR, 5.68, 95% CI, 1.26–25.67) but not nonsteroidal MRAs (RR, 0.52, 95% CI, 0.22–1.22) increased the risk of breast disorders. Conclusions: In the CKD patients, MRAs, particularly in combination with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, reduced albuminuria/proteinuria, eGFR, and the incidence of chronic renal failure, cardiovascular and peripheral edema events, whereas increasing the incidence of hyperkalemia and hypotension, without the augment of acute kidney injury events. Nonsteroidal MRAs were superior in the reduction of more albuminuria with fewer peripheral edema events and without the augment of breast disorder events.
A Patent Review of Aldosterone Synthase Inhibitors (2014-Present)

Jun Wu,Xiao Ding,Xuefei Tan

DOI: https://doi.org/10.1080/13543776.2021.1965991

2021-01-01

Expert Opinion on Therapeutic Patents

Abstract:ABSTRACT Introduction Aldosterone synthase (AS) is a key enzyme involved in the final three rate-limiting steps of the biosynthesis pathway of aldosterone, and its inhibition has been considered as an effective strategy to treat hypertension, heart failure, and related cardio-metabolic diseases. Area covered This review provides an update on the discovery and development of aldosterone synthase inhibitors by means of patents published between January 2014 and March 2021. The molecules are classified by pharmaceutical company with progress that has been made in clinical trials being highlighted. Expert opinion Mineralocorticoid receptor antagonists (MRAs) and aldosterone synthase inhibitors (ASI) represent two of the main approaches for the blockade of aldosterone. Clinical success, as well as foreseen side effects of steroidal MRAs, prompted the discovery and development of ASI. Since the observation of decreased cortisol levels in clinical trials for LCI699, subsequent efforts have been largely focused on improving its selectivity over hCYP11B1. Candidates with improved potency and selectivity are under investigation across a wide range of indications. Whether ASI will provide an additional therapeutic advantage over current safe and selective non-steroidal MRAs is highly anticipated.
Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatment

Cuiyu Guo,Guangbing Zhang,Chengyong Wu,Yi Lei,Yuxi Wang,Jinliang Yang

DOI: https://doi.org/10.1016/j.ejmech.2024.116521

2024-08-05

Abstract:Aldosterone synthase (CYP11B2) is the rate-limiting enzyme in aldosterone production. In recent years, CYP11B2 has become an appealing target for treating conditions associated with excess aldosterone, such as hypertension, heart failure, and cardiometabolic diseases. Several small-molecule inhibitors of CYP11B2 have demonstrated efficacy in both preclinical studies and clinical trials. Among them, the tetrahydroisoquinoline derivative Baxdrostat has entered clinical trial phases and demonstrated efficacy in treating patients with hypertension. However, the high homology (>93 %) between CYP11B2 and steroid-11β-hydroxylase (CYP11B1), which catalyzes cortisol production, implies that insufficient drug specificity can lead to severe side effects. Developing selective inhibitors for CYP11B2 remains a considerable challenge that requires ongoing attention. This review summarizes recent research progress on small-molecule inhibitors targeting CYP11B2, focusing on structure-activity relationships (SAR) and structural optimization. It discusses strategies for enhancing the specificity and inhibitory activity of inhibitors, while also exploring potential applications and future prospects for CYP11B2 inhibitors, providing a theoretical foundation for developing the new generation of CYP11B2-targeted medications.
New ways of mitigating aldosterone in cardiorenal disease

Felix Götzinger,Michael Kunz,Lucas Lauder,Michael Böhm,Felix Mahfoud

DOI: https://doi.org/10.1093/ehjcvp/pvae049

2024-10-04

Abstract:Steroidal mineralocorticoid receptor antagonists (MRAs) bind to the mineralocorticoid receptor and antagonize the effects of aldosterone, which contributes to the development and progression of cardio- and renovascular diseases. Guidelines recommend steroidal MRAs in patients with heart failure with reduced or mildly reduced ejection fraction, as they reduce morbidity and mortality. In heart failure with preserved ejection fraction, MRAs have not convincingly shown to improve prognosis. Steroidal MRAs delay the progression of chronic kidney disease, reduce proteinuria and lower blood pressure in resistant hypertension but can induce hyperkalaemia. Due to their limited selectivity to the mineralocorticoid receptor, steroidal MRAs can cause significant adverse effects, i.e. libido loss, erectile dysfunction, gynaecomastia, and amenorrhoea, leading to low rates of persistance. Against this background, new avenues for developing non-steroidal, selective (ns)MRAs and aldosterone-synthase inhibitors have been taken. Finerenone has been shown to delay the progression of diabetic nephropathy and lower the incidence of heart failure hospitalizations in patients with chronic kidney disease and diabetes compared with placebo. Finerenone has therefore been recommended by the 2023 European Society of Cardiology Guidelines for the management of diabetes in patients with type 2 diabetes and chronic kidney disease. Further randomized controlled trials assessing the safety and effectiveness of finerenone in patients with heart failure are currently ongoing. Esaxerenone provides antihypertensive effects and has been approved for the treatment of hypertension in Japan. Baxdrostat and lorundostat, novel selective aldosterone-synthase inhibitors, are currently under investigation. In phase II trials, baxdrostat and lorundostat were safe and effective in lowering blood pressure in resistant hypertension. In this review, we summarize and critically discuss the evidence for new drugs mitigating aldosterone in heart failure, hypertension, and chronic kidney disease.
Effects of kassinin, a tachykinin of the skin of the African frog Kassina senegalensis, on body fluid homeostasis in rats.

M. Perfumi,G. de Caro,I. Panocka,C. Polidori,M. Massi

DOI: https://doi.org/10.1016/S0031-6989(88)80843-9

1988-12-01

Pharmacological Research Communications

Abstract:
Aldosterone's impact on kidney health: exploring the benefits of mineralocorticoid receptor antagonists for renal protection

Zige Liu,Boji Xie,Shuting Pang,Yuli Xie,Mujia Jili,Zengnan Mo,Wei Li,Rirong Yang

DOI: https://doi.org/10.62347/NRGG6465

2024-08-15

Abstract:Aldosterone, a hormone synthesized by the adrenal cortex, plays a crucial role in regulating sodium and potassium levels in the kidneys through interaction with the mineralocorticoid receptor (MR) in the distal tubules and collecting ducts. While aldosterone aids in maintaining fluid balance by promoting sodium reabsorption and potassium secretion, elevated levels can lead to inflammation, oxidative stress, and organ damage. Experimental evidence highlights aldosterone's involvement in renal inflammation, collagen deposition, and fibrosis, often exacerbating the effects of therapies like angiotensin-converting enzyme inhibitors (ACEIs) by increasing proteinuria and vascular damage. Conversely, mineralocorticoid receptor antagonists (MRAs) show promise in mitigating these harmful effects. This review integrates current knowledge on aldosterone and MRAs, emphasizing their roles in renal health from both clinical and experimental perspectives. Additionally, the novel drug finerenone has shown favorable renal and cardiovascular outcomes in patients with diabetes and chronic kidney disease (CKD), warranting exploration of its potential use in other disease populations in future research.
Aldosterone Synthase Inhibitors and Dietary Interventions: A Combined Novel Approach for Prevention and Treatment of Cardiovascular Disease

Ayoola Awosika,Anosh Khan,Uzochukwu Adabanya,Adekunle E Omole,Richard M Millis

DOI: https://doi.org/10.7759/cureus.36184

2023-03-15

Cureus

Abstract:Systemic hypertension (HTN) is the hallmark of cardiovascular disease and the forerunner of heart failure. These associations have been established over decades of research on essential HTN. Advancements in the treatment of patients diagnosed with HTN, consisting of alpha- or beta-adrenergic receptor blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, thiazide, or aldosterone receptor blockers known as anti-mineralocorticoids, in the presence or absence of low sodium salt diets, often fail to control blood pressure adequately to prevent morbidity and mortality. Low sodium diets have had limited success in controlling HTN because low sodium intake is associated with renin-angiotensin-aldosterone system upregulation. Therefore, upregulating aldosterone secretion, sodium, and water retention which, in turn, moves the blood pressure back toward the range of HTN dictated by the baroreceptor reset value, as a compensatory mechanism, especially in resistant HTN. These impediments to blood pressure control in HTN may have been effectively circumvented by the advent of a new class of drugs known as aldosterone synthase inhibitors, represented by baxdrostat. The mechanism of action of baxdrostat as an aldosterone synthase inhibitor demonstrates the inextricable linkage between sodium and blood pressure regulation. Theoretically, combining a low sodium diet with the activity of this aldosterone synthesis inhibitor should alleviate the adverse effect of renin-angiotensin-aldosterone system upregulation. Aldosterone synthesis inhibition should also decrease the oxidative stress and endothelial dysfunction associated with HTN, causing more endothelial nitric oxide synthesis, release, and vasorelaxation. To the best of our knowledge, this is the first systematic review to summarize evidence-based articles relevant to the use of a novel drug (aldosterone synthase inhibitor) in the treatment of HTN and cardiovascular disease. Making the current database of relevant information on baxdrostat and other aldosterone synthase inhibitors readily available will, no doubt, aid physicians and other medical practitioners in their decision-making about employing aldosterone synthase inhibitors in the treatment of patients.
A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function

John M C Connell,Scott M MacKenzie,E Marie Freel,Robert Fraser,Eleanor Davies

DOI: https://doi.org/10.1210/er.2007-0030

Abstract:Up to 15% of patients with essential hypertension have inappropriate regulation of aldosterone; although only a minority have distinct adrenal tumors, recent evidence shows that mineralocorticoid receptor activation contributes to the age-related blood pressure rise and illustrates the importance of aldosterone in determining cardiovascular risk. Aldosterone also has a major role in progression and outcome of ischemic heart disease. These data highlight the need to understand better the regulation of aldosterone synthesis and its action. Aldosterone effects are mediated mainly through classical nuclear receptors that alter gene transcription. In classic epithelial target tissues, signaling mechanisms are relatively well defined. However, aldosterone has major effects in nonepithelial tissues that include increased synthesis of proinflammatory molecules and reactive oxygen species; it remains unclear how these effects are controlled and how receptor specificity is maintained. Variation in aldosterone production reflects interaction of genetic and environmental factors. Although the environmental factors are well understood, the genetic control of aldosterone synthesis is still the subject of debate. Aldosterone synthase (encoded by the CYP11B2 gene) controls conversion of deoxycorticosterone to aldosterone. Polymorphic variation in CYP11B2 is associated with increased risk of hypertension, but the molecular mechanism that accounts for this is not known. Altered 11beta-hydroxylase efficiency (conversion of deoxycortisol to cortisol) as a consequence of variation in the neighboring gene (CYP11B1) may be important in contributing to altered control of aldosterone synthesis, so that the risk of hypertension may reflect a digenic effect, a concept that is discussed further. There is evidence that a long-term increase in aldosterone production from early life is determined by an interaction of genetic and environmental factors, leading to the eventual phenotypes of aldosterone-associated hypertension and cardiovascular damage in middle age and beyond. The importance of aldosterone has generated interest in its therapeutic modulation. Disadvantages associated with spironolactone (altered libido, gynecomastia) have led to a search for alternative mineralocorticoid receptor antagonists. Of these, eplerenone has been shown to reduce cardiovascular risk after myocardial infarction. The benefits and disadvantages of this therapeutic approach are discussed.
Aldosterone: Essential for Life but Damaging to the Vascular Endothelium

Michael Crompton,Laura J Skinner,Simon C Satchell,Matthew J Butler

DOI: https://doi.org/10.3390/biom13061004

IF: 6.064

2023-06-17

Biomolecules

Abstract:The renin angiotensin aldosterone system is a key regulator of blood pressure. Aldosterone is the final effector of this pathway, acting predominantly via mineralocorticoid receptors. Aldosterone facilitates the conservation of sodium and, with it, water and acts as a powerful stimulus for potassium excretion. However, evidence for the pathological impact of excess mineralocorticoid receptor stimulation is increasing. Here, we discussed how in the heart, hyperaldosteronism is associated with fibrosis, cardiac dysfunction, and maladaptive hypertrophy. In the kidney, aldosterone was shown to cause proteinuria and fibrosis and may contribute to the progression of kidney disease. More recently, studies suggested that aldosterone excess damaged endothelial cells. Here, we reviewed how damage to the endothelial glycocalyx may contribute to this process. The endothelial glycocalyx is a heterogenous, negatively charged layer on the luminal surface of cells. Aldosterone exposure alters this layer. The resulting structural changes reduced endothelial reactivity in response to protective shear stress, altered permeability, and increased immune cell trafficking. Finally, we reviewed current therapeutic strategies for limiting endothelial damage and suggested that preventing glycocalyx remodelling in response to aldosterone exposure may provide a novel strategy, free from the serious adverse effect of hyperkalaemia seen in response to mineralocorticoid blockade.
Transmission and prevalence of Burkholderia cepacia in Welsh cystic fibrosis patients.

L. Millar-Jones,H. Ryley,A. Paull,M. Goodchild

DOI: https://doi.org/10.1016/S0954-6111(98)90092-0

IF: 4.3

1998-02-01

Respiratory Medicine

Abstract:
Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit?

Bi Huang,Garry McDowell,Anirudh Rao,Gregory Y.H. Lip

DOI: https://doi.org/10.1097/hjh.0000000000003643

IF: 4.9

2024-02-01

Journal of Hypertension

Abstract:The renin-angiotensin-aldosterone system (RAAS) is an important regulator of cardiac, vascular, and renal physiology via the regulation of vascular tone and salt and water homeostasis. However, overactivation of RAAS plays a critical role in various pathophysiological conditions such as hypertension, heart failure, and chronic kidney disease (CKD). Blockade of RAAS overactivation has been shown to improve the outcome in various cardiovascular and renal diseases [1,2] . In the setting of CKD, aldosterone becomes dysregulated. First, the circulating aldosterone level is increased and the aldosterone receptor sensitivity and binding affinity is upregulated [3] . Aldosterone receptor activation in CKD promotes renal fibrosis by stimulating profibrotic pathways via upregulation of plasminogen activator inhibitor, transforming growth factor β1, interleukin-6, monocyte chemoattractant protein-1, and so on, leading to excessive collagen deposition and tissue remodeling, further exacerbating renal damage and promoting kidney disease progression [4] . Therefore, mineralocorticoid receptor antagonists (MRA) further inhibit the RAAS through direct aldosterone antagonism.

peripheral vascular disease
When to use either spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases

Masatake Kobayashi,Nicolas Girerd,Faiez Zannad

DOI: https://doi.org/10.1093/ndt/gfae004

IF: 7.1857

2024-01-08

Nephrology Dialysis Transplantation

Abstract:Abstract Kidney disease frequently coexists with cardiovascular diseases, and this dual presence significantly amplifies the risk of adverse clinical outcomes. Shared pathophysiological mechanisms and common cardiovascular risk factors contribute to the increased expression of mineralocorticoid receptors, which in turn can drive the progression of chronic cardiovascular-kidney disorder. The steroidal mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone have demonstrated the efficacy in improving patient outcomes in cases of heart failure with reduced ejection fraction or those after a myocardial infarction, but have limited value in patients with chronic kidney disease. The non-steroidal MRA finerenone has now established itself as a foundational guideline-recommended therapy in patients with diabetic kidney disease. To date, these pharmacological agents have been developed in distinct patient populations. The consequences of their distinct pharmacological profiles necessitate further consideration. They have not undergone testing across the entire spectrum of cardiorenal scenarios, and the evidence base is currently being complemented with ongoing trials. In this review, we aim to synthesize the existing body of evidence and chart the future trajectory for the use of spironolactone, eplerenone and finerenone in improving clinical outcomes across the diverse spectrum of cardiorenal diseases. By consolidating the current state of knowledge, we seek to provide valuable insights for informed decision-making in the management of patients with these complex and interconnected conditions.

urology & nephrology,transplantation
Mineralocorticoid receptor antagonists and reno‐protection: What's the evidence & where do they fit? A guide for non‐specialists

George Bakris

DOI: https://doi.org/10.1111/dom.15617

2024-05-09

Diabetes Obesity and Metabolism

Abstract:The role of aldosterone has yet to be well appreciated in chronic kidney disease (CKD). Two variables define CKD: an estimated glomerular filtration rate of 30 mg/g. Both are needed for an accurate diagnosis. The presence of CKD at this level is associated with an elevated risk of cardiovascular death and a greater risk of CKD progression to kidney failure and subsequent dialysis. This paper presents an overview of aldosterone's importance in CKD and its contribution to the inflammatory processes involved in CKD development. Data on outcomes, both surrogate and hard, related to outcomes on CKD progression will also be discussed in the context of mineralocorticoid blockade. Based on recent epidemiological data as well as data examining markers of diabetic kidney disease progression, it is clear that use of both renin‐angiotensin system inhibitors and aldosterone receptor antagonists have a significant role in altering the natural history of kidney disease progression itself, as well as reducing the risk of cardiovascular events that generally accompany long‐standing kidney disease. This paper will discuss these issues and the management of consequent hyperkalaemia when both steroidal and non‐steroidal mineralocorticoid receptor antagonists are used in detail.

endocrinology & metabolism
[Research progress on the cardiorenal protection of non-steroid mineralocorticoid receptor antagonists in patients with chronic kidney disease]

Wen-Yu Liu,Sheng-Qiang Yu

2022-12-25

Abstract:Mineralocorticoid receptor antagonists not only are used as a diuretics to treat essential hypertension, but also protect the heart and kidney by inhibiting inflammation and fibrosis. Since the discovery of spironolactone, the first generation of mineralocorticoid receptor antagonist, two types of non-steroid mineralocorticoid receptor antagonists (finerenone and esaxerenone) approved for clinical use have been developed, which have the advantages of high affinity, high selectivity and balanced distribution in heart and kidney, and can be used in clinic as a cardiorenal protective drug. In this paper, the development history of mineralocorticoid receptor antagonists was reviewed, and the pathophysiological mechanism of inflammation and fibrosis caused by mineralocorticoid receptors and the similarities and differences of different generations of mineralocorticoid receptor antagonists were analyzed. In particular, the phase III clinical research evidence of finerenone and esaxerenone was discussed. This paper also reviews the research progress of cardiorenal protection of non-steroid mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Effects of aldosterone on coronary function

Ludovic Benard,Paul Milliez,Marie-Lory Ambroisine,Smail Messaoudi,Jane-Lise Samuel,Claude Delcayre

DOI: https://doi.org/10.1016/s1734-1140(09)70007-6

Abstract:Our understanding of the effects of aldosterone and its mechanisms has increased substantially in recent years, probably because of the importance of the mineralocorticoid receptor (MR) antagonists in several major cardiovascular diseases. Recent clinical studies have confirmed the benefits of MR antagonists in patients with heart failure, left ventricular dysfunction after myocardial infarction, hypertension or diabetic nephropathy. However, it would be a gross oversimplification to conclude that the role of aldosterone is unequivocally negative. Aldosterone is synthesized in the adrenal glands and binds to specific MRs in target epithelial cells. The steroid-receptor complex penetrates the cell nucleus where it modulates gene expression and activates specific aldosterone-induced proteins that control sodium reabsorption. Recent studies have shown that aldosterone also impacts a wide range of non-epithelial tissues such as the heart and blood vessels. Remarkably, aldosterone can also be synthesized in extra-adrenal tissues and it may act in a rapid non-genomic manner.We note the existence of glucocorticoids that exhibit plasma concentrations much higher than those of aldosterone and that are structurally very similar to aldosterone. It is thus possible that glucocorticoids may bind to the aldosterone receptor in some cell types. Diverse experimental models and several strains of transgenic mice have allowed us to better understand the effects of aldosterone on the heart. Specifically, it seems that a slight increase in cardiac aldosterone concentrations induces a decreased coronary reserve in mice by decreasing the BKCa potassium channels associated with coronary smooth muscle cells. Taken together, these experiments indicate that vascular cells are the primary targets of aldosterone in the cardiovascular system. The hormone directly affects NO and EDHF-mediated coronary relaxation. Both mechanisms may contribute to the deleterious cardiovascular effects of MR stimulation.
Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries

D Sztechman,K Czarzasta,A Cudnoch-Jedrzejewska,E Szczepanska-Sadowska,T Zera

DOI: https://doi.org/10.26402/jpp.2018.6.01

Abstract:In the review we discuss the role of mineralocorticoid receptors (MRs) in regulation and pathological remodelling of the cardiovascular system and the therapeutic potential of pharmacological targeting of MRs in cardiovascular diseases. MRs are expressed in organs involved in cardiovascular homeostasis: brain, heart, kidneys and vessels. The excessive activation of MRs has deleterious effects on the cardiovascular system through sympatho-excitation, elevated salt appetite, and renal retention of salt with consequent positive sodium balance, fibrosis and remodelling of the heart and arteries, and with propensity for atrial and ventricular arrhythmias. Hence, it provides basis for a common pathophysiological milieu of hypertension and heart failure. Furthermore, MR-mediated changes in the cardiovascular system are potentiated by renin-angiotensin system and activation of angiotensin type 1 receptors. Due to low selectivity, MRs bind both aldosterone and GCs - cortisol in humans and corticosterone in laboratory rodents. The binding of GCs to MRs is determined by availability of tissue specific 11β-hydroxysteroid dehydrogenase of type 1 (11β-HSD1) or type 2 (11β-HSD2). 11β-HSD1 metabolizes GCs to either active or inactive metabolites depending on the presence of special cofactors, whereas 11β-HSD2 transforms GCs only into inactive metabolites allowing for selective stimulation of MRs by aldosterone. 11β-HSD2 is expressed in the vascular wall, renal epithelium and some groups of cardiovascular neurons in the brain. In contrast, cardiac expression of 11β-HSD2 is low, thus, both aldosterone and GCs interact with cardiac MRs. The importance of MRs in the cardiovascular pathology is reflected in clinical guidelines that recommend use of MR blockers, spironolactone and eplerenone, in the treatment of heart failure, myocardial infarction and hypertension. Furthermore, new MR blockers and selective inhibitors of 11β-HSD1 have been developed and are currently tested in clinical trials.
Aldosterone in the Pathogenesis of Chronic Kidney Disease and Proteinuria

Yee Lu,Elaine Ku,Vito M. Campese

DOI: https://doi.org/10.1007/s11906-010-0116-4

2010-07-02

Current Hypertension Reports

Abstract:There has been much recent interest in the role of aldosterone as an independent contributor to the progression of chronic kidney disease. Despite treatment with agents such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, many studies have shown that there is incomplete blockade of the renin-angiotensin cascade evidenced by persistent or rising plasma aldosterone levels despite therapeutic renin-angiotensin blockade. This phenomenon is commonly referred to as “aldosterone escape” and is thought to be one of the main contributors to chronic kidney disease progression despite conventional therapeutics. Animal models of the effects of exposure to exogenous aldosterone demonstrate the development of inflammation and fibrosis in both the myocardium and renal parenchyma. In limited human studies, aldosterone receptor antagonism is associated with decreased proteinuria and improved glomerular filtration rate. Although data support the addition of an aldosterone antagonist to conventional therapy when treating patients with chronic kidney disease, more studies are needed to determine the precise clinical indications and the appropriate safety monitoring.

peripheral vascular disease
[Protozoa from the genus Leukocytozoon in birds from the vicinity of Wroclaw].

A. Ramisz

Abstract:
Aldosterone: Renal Action and Physiological Effects

Jermaine G. Johnston,Amanda K. Welch,Brian D. Cain,Peter P. Sayeski,Michelle L. Gumz,Charles S. Wingo

DOI: https://doi.org/10.1002/cphy.c190043

IF: 5.8

2024-11-09

Comprehensive Physiology

Abstract:Aldosterone exerts profound effects on renal and cardiovascular physiology. In the kidney, aldosterone acts to preserve electrolyte and acid-base balance in response to changes in dietary sodium (Na^(+) ) or potassium (K^(+) ) intake. These physiological actions, principally through activation of mineralocorticoid receptors (MRs), have important effects particularly in patients with renal and cardiovascular disease as demonstrated by multiple clinical trials. Multiple factors, be they genetic,...

physiology
Accuracy of four transfer impression techniques for dental implants: a scanning electron microscopic analysis.

E. Yamamoto,J. Marotti,T. T. de Campos,P. Neto

2010-11-01

The International Journal of Oral and Maxillofacial Implants

Abstract:PURPOSE The aim of this study was to evaluate, using scanning electron microscopy (SEM), the accuracy of four impression techniques for osseointegrated implants (with or without acrylic resin splinting and with irreversible hydrocolloid or polyvinyl siloxane [PVS] impression material). MATERIALS AND METHODS A metal master model was made with three implant analogs and two prosthetic spaces. This model was used as the standard for all impressions. Two impression materials were used (irreversible hydrocolloid and PVS) and two transfer techniques were used (squared impression copings indexed by the impression material and squared impression copings splinted with acrylic resin). Four groups were therefore analyzed (n = 5): IH = irreversible hydrocolloid only, IHS = irreversible hydrocolloid + splint, P = PVS only, and PS = PVS + splint. A reference framework made with palladium-silver alloy over the UCLA abutment was created on the master model. The fit of this structure to the master model was used as a reference. SEM images of the front and side gaps between the abutments and the implant analogs were created and then measured using image analysis software. RESULTS IH presented the largest misfit. The splinted impression copings generated a smaller marginal gap than the indexed material technique, irrespective of the impression material used. There was no significant difference between IHS, P, PS, and the reference (multivariate test, Wilks criteria). However, PS presented a standard deviation that was three times lower than those of the other groups, and its mean was closer to the reference. CONCLUSIONS The IH impression technique was the least accurate technique. There was no difference between IHS, P, and PS techniques with regard to the reference constant. The impression techniques that used splinted impression copings generated more accurate casts, irrespective of the impression material.

CC chemokine receptor 5 influences late-stage atherosclerosis.

Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis

A Patent Review of Aldosterone Synthase Inhibitors (2014-Present)

Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatment

New ways of mitigating aldosterone in cardiorenal disease

Effects of kassinin, a tachykinin of the skin of the African frog Kassina senegalensis, on body fluid homeostasis in rats.

Aldosterone's impact on kidney health: exploring the benefits of mineralocorticoid receptor antagonists for renal protection

Aldosterone Synthase Inhibitors and Dietary Interventions: A Combined Novel Approach for Prevention and Treatment of Cardiovascular Disease

A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function

Aldosterone: Essential for Life but Damaging to the Vascular Endothelium

Transmission and prevalence of Burkholderia cepacia in Welsh cystic fibrosis patients.

Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit?

When to use either spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases

Mineralocorticoid receptor antagonists and reno‐protection: What's the evidence & where do they fit? A guide for non‐specialists

[Research progress on the cardiorenal protection of non-steroid mineralocorticoid receptor antagonists in patients with chronic kidney disease]

Effects of aldosterone on coronary function

Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries

Aldosterone in the Pathogenesis of Chronic Kidney Disease and Proteinuria

[Protozoa from the genus Leukocytozoon in birds from the vicinity of Wroclaw].

Aldosterone: Renal Action and Physiological Effects

Accuracy of four transfer impression techniques for dental implants: a scanning electron microscopic analysis.